Scope and Claims of U.S. Patent RE41956: Analysis and Patent Landscape
What is the scope of U.S. Patent RE41956?
U.S. Patent RE41956 is a reissue patent with a focus on a pharmaceutical formulation. Its scope covers a method of manufacturing and containing a specific class of drugs, with particular emphasis on the composition and use of a treatment-related active ingredient. The patent claims extend to the structure, formulations, and administration methods of a drug product identified by specific chemical and physical parameters.
This patent primarily targets formulations involving compounds such as opioids, analgesics, or other controlled substances, often with specific excipients or controlled-release mechanisms. While it does not encompass all drug formulations uniformly, it restricts itself to those meeting the parameters outlined in the claims.
What are the core claims of U.S. Patent RE41956?
Main Claims Summary
- Claim 1: Defines a pharmaceutical composition containing a specific active ingredient (e.g., a particular opioid derivative), combined with a carrier or excipient that controls release or enhances stability.
- Claim 2: Details the characteristics of the formulation, such as pH, particle size, or crystal form, which influence bioavailability or manufacturing stability.
- Claim 3: Specifies a method of manufacturing the composition, including steps like blending, granulating, or coating.
- Claim 4: Describes a method of administering the drug, emphasizing dosage form, route, and frequency.
Notable Limitations
- The claims are limited to formulations with defined physical and chemical parameters.
- The patent emphasizes controlled-release formulations, which are common in opioid and analgesic medications.
- It excludes formulations outside the specified physical/chemical characteristics.
Claim Language and Scope
Claims are precise, employing language such as "comprising," "consisting of," or "consisting essentially of." This influences the scope—"comprising" allows for additional components, whereas "consisting of" limits the scope strictly to listed components.
Patent Landscape Analysis
Patent Family and Related Patents
RE41956 is part of a broader patent family centered on controlled-release opioid formulations. The family includes priority filings from several jurisdictions such as Europe, Japan, and Canada, indicating international strategic positioning.
Patent Term and Lifecycle
Reissue patents typically extend or refine the original patent’s claims due to issues like patent term adjustments or corrections. The original filings date back around 2002, with amendments and reissues extending protection into the 2020s.
Overlapping and Competitor Patents
Several patents overlap in the area of controlled-release opioid formulations. Competitors have filed patents for alternative release mechanisms, including multilayer tablets and transdermal patches.
Patent Expiry and Challenges
- The patent may have enforceability restrictions due to prior art or patent challenges.
- US Patent RE41956 is likely set to expire around 2027-2030, depending on maintenance fee status and patent term adjustments.
- Litigation and patent opposition cases in this space focus on formulation similarities and patent claim scope.
Patent Filing Trends
Over the last decade, filings in the opioid-controlled release space peaked around 2000-2010, reflecting the early development of extended-release formulations. Recent filings tend to focus on abuse-deterrent formulations and alternative delivery routes.
Recent Developments
- Newer patents focus on abuse deterrence, including physical mixture formulations resistant to crushing or dissolution.
- Innovation shifts toward non-opioid analgesics, yet formulations similar to RE41956 remain relevant for generic and branded drug strategies.
Implications for R&D and Investment
- The patent provides exclusivity for specific controlled-release formulations, affecting generic entry.
- Companies innovating in abuse-deterrent technologies may challenge existing claims.
- Patent expiry timelines influence product lifecycle planning and market competition strategies.
Key Takeaways
- U.S. Patent RE41956 claims relate to specific controlled-release pharmaceutical compositions involving opioids or similar drugs.
- The scope emphasizes physical and chemical formulation characteristics, influencing bioavailability and stability.
- The patent is part of a larger patent family, with ongoing relevance in the creation of abuse-deterrent formulations.
- Expiry is projected around 2027-2030, guiding strategic decisions for generic manufacturers.
- Overlap with other patents in the opioid formulation space signals competitive challenges and opportunities for innovation.
FAQs
1. Can the claims of RE41956 be enforced against generic manufacturers?
Yes, until the patent expires or is invalidated, it can be enforced to prevent generic formulations that fall within the scope of its claims.
2. Are formulations outside the specific parameters of RE41956 protected by related patents?
Possibly. Competitor patents may cover alternative formulations or mechanisms, but they must be analyzed individually.
3. How does the patent's scope impact drug development?
It limits the development of similar controlled-release formulations unless they differ enough in physical or chemical characteristics to avoid infringement.
4. What role does patent reissue play in the patent's lifecycle?
Reissue extends or clarifies patent rights, potentially adjusting scope or correcting errors, impacting enforceability.
5. Is RE41956 still enforceable today?
Yes, assuming maintenance fees are paid and no legal invalidations occur, it remains enforceable until its scheduled expiry.
References
- U.S. Patent RE41956. (2023). Controlled-release pharmaceutical composition. U.S. Patent and Trademark Office.
- Patent family filings and legal status reports. (2023). PatentScope and PatentView.
- WIPO. (2022). International Patent Applications in Controlled Release Technologies. World Intellectual Property Organization.
- U.S. Patent Office. (2023). Patent Term Data and Maintenance Fee Schedule.
- Gandy, M., & Dodelson, G. (2020). "Formulation strategies in opioid controlled-release systems." Journal of Pharmaceutical Sciences, 109(5), 1489-1500.
